Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.82 USD | -1.05% | +0.45% | +9.88% |
May. 13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
Financials (USD)
Sales 2024 * | 583M | Sales 2025 * | 597M | Capitalization | 1.11B |
---|---|---|---|---|---|
Net income 2024 * | 121M | Net income 2025 * | 148M | EV / Sales 2024 * | 2.15 x |
Net Debt 2024 * | 146M | Net cash position 2025 * | 194M | EV / Sales 2025 * | 1.53 x |
P/E ratio 2024 * |
11.2
x | P/E ratio 2025 * |
9.05
x | Employees | 197 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.46% |
Latest transcript on Collegium Pharmaceutical, Inc.
1 day | -1.05% | ||
1 week | +0.45% | ||
Current month | -8.42% | ||
1 month | -5.90% | ||
3 months | -6.96% | ||
6 months | +30.18% | ||
Current year | +9.88% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 01-12-31 | |
Joseph Ciaffoni
CEO | Chief Executive Officer | 53 | 17-05-30 |
Colleen Tupper
DFI | Director of Finance/CFO | 48 | 21-05-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 14-12-31 |
Gino Santini
BRD | Director/Board Member | 66 | 12-07-23 |
John Freund
BRD | Director/Board Member | 70 | 14-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.25% | 28 M€ | -2.47% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 33.82 | -1.05% | 297,651 |
24-05-22 | 34.18 | -0.93% | 274,088 |
24-05-21 | 34.5 | +1.02% | 343,823 |
24-05-20 | 34.15 | +5.17% | 404,722 |
24-05-17 | 32.47 | -3.56% | 385,347 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.88% | 1.11B | |
+38.69% | 728B | |
+34.26% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+16.30% | 244B | |
+7.80% | 207B | |
-5.24% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- COLL Stock